Persistent enhancement after treatment for cerebral toxoplasmosis in patients with AIDS: predictive value for subsequent recurrence.
OBJECTIVE
To determine the predictive imaging (CT and/or MR) features of brain toxoplasmosis recurrences in acquired immunodeficiency syndrome.


METHODS
The imaging studies of patients with brain toxoplasmosis were retrospectively reviewed. Forty-three patients with significant decrease or disappearance of brain lesions under specific treatment on follow-up imaging examinations were included. MR examinations were performed using T2- and T1-weighted sequences, before and after intravenous administration of gadolinium-DOTA.


RESULTS
A recurrence occurred in 11 (26%) of 43 cases. Ten (91%) of these 11 patients with recurrence showed focal persistent enhancement after the initial treatment of toxoplasmosis abscess. One of the 11 patients with recurrence showed no persistent enhancement; 3 patients showed persistent enhancement but had no recurrence.


CONCLUSIONS
Recurrences of brain toxoplasmosis in our series correlated with persistent contrast enhancement. We hypothesize that demonstration of persistent areas of contrast enhancement after treatment for initial toxoplasmosis may be a valuable sign for identifying patients at risk for recurrence.
Department of Radiology, Hôpital Bichat, Paris, France.
J P
JP
Laissy
P
P
Soyer
C
C
Parlier
S
S
Lariven
Z
Z
Benmelha
V
V
Servois
E
E
Casalino
E
E
Bouvet
A
A
Sibert
F
F
Vachon
D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D001284:Atrophy; D001921:Brain / Q000473:pathology; D001922:Brain Abscess / Q000175:diagnosis / Q000188:drug therapy; D004359:Drug Therapy, Combination; D004678:Encephalomalacia / Q000175:diagnosis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D011739:Pyrimethamine / Q000627:therapeutic use*; D012008:Recurrence; D013411:Sulfadiazine / Q000627:therapeutic use*; D016781:Toxoplasmosis, Cerebral / Q000175:diagnosis / Q000188:drug therapy*
D013411:Sulfadiazine; D011739:Pyrimethamine